The Tidewater Multispecialty Group Clinical Research Division in Williamsburg is investigating a new oral medication, Molnupiravir, for the possible prevention of COVID-19 in COVID-positive households.
According to a press release, the trial will aim to prevent unvaccinated individuals from contracting COVID-19 in households where one individual has recently tested positive for COVID-19. This is in contrast to the usage for the drug that pharmaceutical company Merck recently announced it will be submitting to the FDA for emergency approval, which is to treat those who are already COVID-positive.
If approved by the FDA and other regulatory bodies, this would be the first oral antiviral medication to prevent the transmission of COVID-19, said the release.
The antiviral is a pill taken twice a day for five days, said the release, and it works to prevent transmission of the virus by fighting off the virus inside the body. The trial will be placebo-controlled, meaning participants...
To view the rest of this article, you must log in. If you do not have an account with us, please subscribe here.